Cocrystal Pharma, Inc.
COCP
$1.31
$0.010.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 49.55% | 48.29% | 29.94% | 5.38% | 2.67% |
| Total Depreciation and Amortization | -42.86% | -36.96% | -67.53% | -50.48% | -33.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -63.75% | -62.38% | -18.83% | -6.19% | -4.32% |
| Change in Net Operating Assets | 110.00% | -130.90% | -150.64% | 197.93% | -94.02% |
| Cash from Operations | 50.31% | 42.25% | 5.86% | 7.08% | -12.40% |
| Capital Expenditure | -50.00% | 82.09% | 100.00% | 100.00% | 93.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -50.00% | 82.09% | 100.00% | 100.00% | 93.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.81% | 68.35% | 6.30% | -22.92% | -52.84% |